Wikipedia
Heberprot-P is the brand name of a drug developed by scientists at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba as a cure for diabetic foot ulcer. The product contains epidermal growth factor (EGF) to be applied by intra-lesional injections directly in the wound site. It has been found to "promote granulation and healing in advanced diabetic foot ulcers". Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 and 5 of Wagner's Classification with average ulcer size bigger than 20 cm, of both neuropathic and ischemic etiology with high risk amputation. Clinical studies in 344 patients with advanced diabetic foot ulcers (Wagner´s grade 3 or 4, median size >20 cm, ischemic ulcers not excluded) have shown that injected recombinant EGF has the potential to promote complete granulation in more than 80%, with complete wound healing (re-epithelialization) in more than 50% of subjects usually unresponsive to other treatments. Injected recombinant EGF has the potential to reduce amputation rates, with a considerable personal and public health improvement, including longer survival.